Overview
The purpose of this study is to assess the feasibility of conducting a randomized controlled efficacy trial comparing the delivery of exposure therapy via a telemedicine-based virtual reality clinic (Doxy.me VR) vs. standard telemental health (TMH) to adults with intense fear of dogs, snakes, and/or spiders. The secondary purpose is to preliminarily examine the efficacy of using Doxy.me VR vs. TMH in reducing phobia severity.
Description
This study aims to assess the feasibility of conducting a randomized controlled efficacy trial comparing the delivery of exposure therapy via a telemedicine-based virtual reality clinic (Doxy.me VR) vs. standard telemental health (TMH) to adults with intense fear of dogs, snakes, and/or spiders. This study will use feasibility randomized controlled efficacy trial design. This single-site trial will include up to 60 adults with self-reported fear of dogs, snakes, and/or spiders who will be randomly assigned via the REDCap Randomization Module using a 1:1 allocation ratio to receive 12 sessions of exposure therapy over the course of 3 months via standard telemental health (TMH; n=15) vs. Doxy.me VR (n=15), a telemedicine-based virtual reality clinic.
Eligibility
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the
following criteria:
1. Is an adult ≥ 18 years old
2. Has a self-reported fear of dogs, snakes, and/or spiders
3. Indicates Subthreshold or Present Specific Phobia symptoms as determined by the study
therapist via administration of the Diagnostic Assessment Research Tool (DART)
Specific Phobia Module
4. Has access to the internet AND a computer OR smartphone with video conferencing
capabilities
5. Will reside in the state of Florida for the duration of the study
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation
in this study:
1. Is participating in ongoing mental health therapy from a non-study therapist
2. Has had changes to psychotropic medication use within six weeks preceding enrollment
in the trial
3. Reports active suicidal and/or homicidal intent or plan as determined by the study
therapist via administration of the Diagnostic Assessment Research Tool (DART) Risk
Assessment Module
4. Reports active auditory, visual, and/or tactile hallucinations via the Diagnostic
Assessment Research Tool (DART) Psychosis Module screening question
5. Reports a history of epilepsy or seizures